Neuroprotective Effects of Aldehyde-Reducing Composition in an LPS-Induced Neuroinflammation Model of Parkinson's Disease

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2023 Dec 23

PMID 38138478

Authors

Sora Kang

Youngjin Noh

Seung Jun Oh

Hye Ji Yoon

Suyeol Im

Hung Taeck Kwon

Youngmi Kim Pak

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is a complex neurodegenerative disease in which neuroinflammation and oxidative stress interact to contribute to pathogenesis. This study investigates the in vivo neuroprotective effects of a patented yeast extract lysate in a lipopolysaccharide (LPS)-induced neuroinflammation model. The yeast extract lysate, named aldehyde-reducing composition (ARC), exhibited potent antioxidant and anti-aldehyde activities in vitro. Oral administration of ARC at 10 or 20 units/kg/day for 3 days prior to intraperitoneal injection of LPS (10 mg/kg) effectively preserved dopaminergic neurons in the substantia nigra (SN) and striatum by preventing LPS-induced cell death. ARC also normalized the activation of microglia and astrocytes in the SN, providing further evidence for its neuroprotective properties. In the liver, ARC downregulated the LPS-induced increase in inflammatory cytokines and reversed the LPS-induced decrease in antioxidant-related genes. These findings indicate that ARC exerts potent antioxidant, anti-aldehyde, and anti-inflammatory effects in vivo, suggesting its potential as a disease-modifying agent for the prevention and treatment of neuroinflammation-related diseases, including Parkinson's disease.

Citing Articles

Monoamine Oxidase Inhibitors in Toxic Models of Parkinsonism.

Buneeva O, Medvedev A Int J Mol Sci. 2025; 26(3).

PMID: 39941014 PMC: 11818313. DOI: 10.3390/ijms26031248.

A Compound Containing Aldehyde Dehydrogenase Relieves the Effects of Alcohol Consumption and Hangover Symptoms in Healthy Men: An Open-Labeled Comparative Study.

Jeong I, Han A, Jun J, Hwang Y, Ahn K, Chung H Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204192 PMC: 11357502. DOI: 10.3390/ph17081087.

References

Grigoryan R, Costas-Rodriguez M, Van Wonterghem E, Vandenbroucke R, Vanhaecke F . Effect of Endotoxemia Induced by Intraperitoneal Injection of Lipopolysaccharide on the Mg isotopic Composition of Biofluids and Tissues in Mice. Front Med (Lausanne). 2021; 8:664666. PMC: 8342922. DOI: 10.3389/fmed.2021.664666. View

Im S, Kang S, Kim J, Oh S, Pak Y . Low-Dose Dioxin Reduced Glucose Uptake in C2C12 Myocytes: The Role of Mitochondrial Oxidative Stress and Insulin-Dependent Calcium Mobilization. Antioxidants (Basel). 2022; 11(11). PMC: 9686767. DOI: 10.3390/antiox11112109. View

Bachiller S, Jimenez-Ferrer I, Paulus A, Yang Y, Swanberg M, Deierborg T . Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response. Front Cell Neurosci. 2019; 12:488. PMC: 6305407. DOI: 10.3389/fncel.2018.00488. View

Cagle B, Crawford R, Doorn J . Biogenic Aldehyde-Mediated Mechanisms of Toxicity in Neurodegenerative Disease. Curr Opin Toxicol. 2019; 13:16-21. PMC: 6625780. DOI: 10.1016/j.cotox.2018.12.002. View

Fitzmaurice A, Rhodes S, Lulla A, Murphy N, Lam H, ODonnell K . Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease. Proc Natl Acad Sci U S A. 2012; 110(2):636-41. PMC: 3545765. DOI: 10.1073/pnas.1220399110. View

Shen Y, Wu Q, Shi J, Zhou S . Regulation of SIRT3 on mitochondrial functions and oxidative stress in Parkinson's disease. Biomed Pharmacother. 2020; 132:110928. DOI: 10.1016/j.biopha.2020.110928. View

Kang S, Lee A, Im S, Oh S, Yoon H, Park J . A Novel Aryl Hydrocarbon Receptor Antagonist HBU651 Ameliorates Peripheral and Hypothalamic Inflammation in High-Fat Diet-Induced Obese Mice. Int J Mol Sci. 2022; 23(23). PMC: 9736602. DOI: 10.3390/ijms232314871. View

Tansey M, Goldberg M . Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis. 2009; 37(3):510-8. PMC: 2823829. DOI: 10.1016/j.nbd.2009.11.004. View

Pan G, Deshpande M, Thandavarayan R, Palaniyandi S . ALDH2 Inhibition Potentiates High Glucose Stress-Induced Injury in Cultured Cardiomyocytes. J Diabetes Res. 2016; 2016:1390861. PMC: 5110883. DOI: 10.1155/2016/1390861. View

10.

Hjelle J, Grubbs J, Petersen D . Inhibition of mitochondrial aldehyde dehydrogenase by malondialdehyde. Toxicol Lett. 1982; 14(1-2):35-43. DOI: 10.1016/0378-4274(82)90007-8. View

11.

Kam T, Hinkle J, Dawson T, Dawson V . Microglia and astrocyte dysfunction in parkinson's disease. Neurobiol Dis. 2020; 144:105028. PMC: 7484088. DOI: 10.1016/j.nbd.2020.105028. View

12.

Uversky V . Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res. 2004; 318(1):225-41. DOI: 10.1007/s00441-004-0937-z. View

13.

Castro J, Jung T, Grune T, Siems W . 4-Hydroxynonenal (HNE) modified proteins in metabolic diseases. Free Radic Biol Med. 2016; 111:309-315. DOI: 10.1016/j.freeradbiomed.2016.10.497. View

14.

Hirsch E, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel P . The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci. 2003; 991:214-28. DOI: 10.1111/j.1749-6632.2003.tb07478.x. View

15.

Salim S . Oxidative Stress and the Central Nervous System. J Pharmacol Exp Ther. 2016; 360(1):201-205. PMC: 5193071. DOI: 10.1124/jpet.116.237503. View

16.

Barrera G, Pizzimenti S, Daga M, Dianzani C, Arcaro A, Cetrangolo G . Lipid Peroxidation-Derived Aldehydes, 4-Hydroxynonenal and Malondialdehyde in Aging-Related Disorders. Antioxidants (Basel). 2018; 7(8). PMC: 6115986. DOI: 10.3390/antiox7080102. View

17.

Liu Y, Zhang Y, Zhu K, Chi S, Wang C, Xie A . Emerging Role of Sirtuin 2 in Parkinson's Disease. Front Aging Neurosci. 2020; 11:372. PMC: 6965030. DOI: 10.3389/fnagi.2019.00372. View

18.

Hirsch E, Hunot S . Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009; 8(4):382-97. DOI: 10.1016/S1474-4422(09)70062-6. View

19.

Wang Y, Gao L, Chen J, Li Q, Huo L, Wang Y . Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson's Disease. Front Pharmacol. 2021; 12:757161. PMC: 8650509. DOI: 10.3389/fphar.2021.757161. View

20.

Burke W, Li S, Williams E, Nonneman R, Zahm D . 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Brain Res. 2003; 989(2):205-13. DOI: 10.1016/s0006-8993(03)03354-7. View